2.1. Monoclonal Antibody-Based Therapies Targeting CD123 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). This evidence concerns the gene IL3RA and CD4+/CD56+ hematodermic neoplasm.